Beta Drugs Limited

NSEI:BETA Rapporto sulle azioni

Cap. di mercato: ₹20.8b

Beta Drugs Gestione

Gestione criteri di controllo 4/4

Beta Drugs Il CEO è Rahul Batra, nominato in Jan2021, e ha un mandato di 3.83 anni. la retribuzione annua totale è ₹ 12.10M, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.41% delle azioni della società, per un valore di ₹ 86.99M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 7.3 anni.

Informazioni chiave

Rahul Batra

Amministratore delegato

₹12.1m

Compenso totale

Percentuale dello stipendio del CEO100.0%
Mandato del CEO3.8yrs
Proprietà del CEO0.4%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione7.3yrs

Aggiornamenti recenti sulla gestione

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rahul Batra rispetto agli utili di Beta Drugs?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Compensazione vs Mercato: La retribuzione totale di Rahul ($USD 143.42K ) è circa la media per le aziende di dimensioni simili nel mercato Indian ($USD 179.34K ).

Compensazione vs guadagni: La retribuzione di Rahul è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Rahul Batra (41 yo)

3.8yrs

Mandato

₹12,100,000

Compensazione

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 85.7m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 71.8m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10mNessun dato
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55kNessun dato
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12mNessun dato
Seema Chopra
Whole Time Directorno data₹1.19mNessun dato
Sanjeev Chopra
Vice President of Technicalno dataNessun datoNessun dato

3.8yrs

Durata media

40.5yo

Età media

Gestione esperta: Il team dirigenziale di BETA è considerato esperto (durata media dell'incarico 3.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 85.7m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 71.8m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12mNessun dato
Seema Chopra
Whole Time Director5.3yrs₹1.19mNessun dato
Manmohan Khanna
Independent Director7.3yrsNessun datoNessun dato
Rohit Parti
Independent Director7.3yrsNessun datoNessun dato

7.3yrs

Durata media

48yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BETA sono considerati esperti (durata media dell'incarico 7.3 anni).